• 1
    Strickberger SA, Conti J, Daoud EG, Havranek E, Mehra MR, Pina IL, Young J. Patient selection for cardiac resynchronization therapy: From the Council on Clinical Cardiology Subcommittee on Electrocardiography and Arrhythmias and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society. Circulation 2005; 111:21462150.
  • 2
    Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346:18451853.
  • 3
    Auricchio A, Stellbrink C, Butter C, Sack S, Vogt J, Misier AR, Bocker D, et al. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol 2003; 42:21092116.
  • 4
    Auricchio A, Stellbrink C, Sack S, Block M, Vogt J, Bakker P, Huth C, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002; 39:20262033.
  • 5
    Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344:873880.
  • 6
    Lozano I, Bocchiardo M, Achtelik M, Gaita F, Trappe HJ, Daoud E, Hummel J, et al. Impact of biventricular pacing on mortality in a randomized crossover study of patients with heart failure and ventricular arrhythmias. Pacing Clin Electrophysiol 2000; 23:17111712.
  • 7
    Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. JAMA 2003; 289:26852694.
  • 8
    Cleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352:15391549.
  • 9
    Moss A, Hall J, Cannom DS, Klein H, Brown MW, Daubert JP, Mark Estes NA III, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361:13291338.
  • 10
    Tang ASL, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH et al. Cardiac-resynchronization therapy for mild-to-moderate heart-failure. N Engl J Med 2010; 363:23852395.
  • 11
    Maskin CS, Forman R, Sonnenblick EH, Frishman WH, LeJemtel TH. Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure. Am J Cardiol 1983; 51:177182.
  • 12
    Harrington D, Anker SD, Chua TP, Webb-Peploe KM, Ponikowski PP, Poole-Wilson PA, Coats AJ. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol 1997; 30:17581764.
  • 13
    Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, Wilson JR. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 1992; 85:13641373.
  • 14
    Bekedam MA, Van Beek-Harmsen BJ, Boonstra A, Van Mechelen W, Visser FC, Van der Laarse WJ. Maximum rate of oxygen consumption related to succinate dehydrogenase activity in skeletal muscle fibres of chronic heart failure patients and controls. Clin Physiol Funct Imaging 2003; 23:337343.
  • 15
    Pina IL, Apstein CS, Balady GJ, Belardinelli R, Chaitman BR, Duscha BD, Fletcher BJ, et al. Exercise and heart failure: A statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention. Circulation 2003; 107:12101225.
  • 16
    Negrao CE, Rondon MU, Tinucci T, Alves MJ, Roveda F, Braga AM, Reis SF, et al. Abnormal neurovascular control during exercise is linked to heart failure severity. Am J Physiol Heart Circ Physiol 2001; 280:H1286H1292.
  • 17
    Notarius CF, Ando S, Rongen GA, Floras JS. Resting muscle sympathetic nerve activity and peak oxygen uptake in heart failure and normal subjects. Eur Heart J 1999; 20:880887.
  • 18
    Grassi G, Vincenti A, Brambilla R, Trevano FQ, Dell'Oro R, Ciro A, Trocino G, et al. Sustained sympathoinhibitory effects of cardiac resynchronization therapy in severe heart failure. Hypertension 2004; 44:727731.
  • 19
    Hamdan MH, Barbera S, Kowal RC, Page RL, Ramaswamy K, Joglar JA, Karimkhani V, et al. Effects of resynchronization therapy on sympathetic activity in patients with depressed ejection fraction and intraventricular conduction delay due to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2002; 89:10471051.
  • 20
    Hamdan MH, Zagrodzky JD, Joglar JA, Sheehan CJ, Ramaswamy K, Erdner JF, Page RL, et al. Biventricular pacing decreases sympathetic activity compared with right ventricular pacing in patients with depressed ejection fraction. Circulation 2000; 102:10271032.
  • 21
    Cohen-Solal A. Cardiopulmonary exercise testing in chronic heart failure. In: Wasserman K (ed.): Cardiopulmonary Exercise Testing and Cardiovascular Health. Armonk, NY, Futura Publishing, 1996, pp. 1735.
  • 22
    Fagius J, Wallin BG. Long-term variability and reproducibility of resting human muscle nerve sympathetic activity at rest, as reassessed after a decade. Clin Auton Res 1993; 3:201205.
  • 23
    Harrington D, Coats AJ. Skeletal muscle abnormalities and evidence for their role in symptom generation in chronic heart failure. Eur Heart J 1997; 18:18651872.
  • 24
    Sullivan MJ, Knight JD, Higginbotham MB, Cobb FR. Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Muscle blood flow is reduced with maintenance of arterial perfusion pressure. Circulation 1989; 80:769781.
  • 25
    Drexler H. Skeletal muscle failure in heart failure. Circulation 1992; 85:16211623.
  • 26
    Kemp GJ, Thompson CH, Stratton JR, Brunotte F, Conway M, Adamopoulos S, Arnolda L, et al. Abnormalities in exercising skeletal muscle in congestive heart failure can be explained in terms of decreased mitochondrial ATP synthesis, reduced metabolic efficiency, and increased glycogenolysis. Heart 1996; 76:3541.
  • 27
    Chati Z, Zannad F, Jeandel C, Lherbier B, Escanye JM, Robert J, Aliot E. Physical deconditioning may be a mechanism for the skeletal muscle energy phosphate metabolism abnormalities in chronic heart failure. Am Heart J 1996; 131:560566.
  • 28
    Coats AJ, Clark AL, Piepoli M, Volterrani M, Poole-Wilson PA. Symptoms and quality of life in heart failure: The muscle hypothesis. Br Heart J 1994; 72(2 Suppl):S36S39.
  • 29
    Sterns DA, Ettinger SM, Gray KS, Whisler SK, Mosher TJ, Smith MB, Sinoway LI. Skeletal muscle metaboreceptor exercise responses are attenuated in heart failure. Circulation 1991; 84:20342039.
  • 30
    Sinoway LI, Li J. A perspective on the muscle reflex: Implications for congestive heart failure. J Appl Physiol 2005; 99:522.
  • 31
    Middlekauff HR, Chiu J, Hamilton MA, Fonarow GC, Maclellan WR, Hage A, Moriguchi J, et al. Muscle mechanoreceptor sensitivity in heart failure. Am J Physiol Heart Circ Physiol 2004; 287:H1937H1943.
  • 32
    Middlekauff HR, Sinoway LI. Point: Counterpoint: Increased mechanoreceptor/metaboreceptor stimulation explains the exaggerated exercise pressor reflex seen in heart failure. J Appl Physiol 2007; 102:492494.
  • 33
    Middlekauff HR. How does cardiac resynchronization therapy improve exercise capacity in chronic heart failure? J Card Fail 2005; 11:534541.
  • 34
    Adamopoulos S, Kemp GJ, Thompson CH, Arnolda L, Brunotte F, Stratton JR, Radda GK, et al. The time course of haemodynamic, autonomic and skeletal muscle metabolic abnormalities following first extensive myocardial infarction in man. J Mol Cell Cardiol 1999; 31:19131926.